Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R D Blumenthal

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Cancer Research|December 11, 1997
Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor typeT M Behr, E Wulst, S Radetzky, et al.
Radiation Research|February 22, 2001
Response to radioimmunotherapy correlates with tumor pO2 measured by EPR oximetry in human tumor xenograftsJ A O'Hara, R D Blumenthal, O Y Grinberg, et al.
Cancer Research|December 1, 1995
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studiesR M Sharkey, M Juweid, J Shevitz, et al.
International Journal of Cancer|August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacyT M Behr, S Memtsoudis, R M Sharkey, et al.
Cancer|December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetryT M Behr, R M Sharkey, G Sgouros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emittersT M Behr, G Sgouros, M G Stabin, et al.
Cancer Research|September 1, 1995
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivativesT M Behr, R M Sharkey, M E Juweid, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1997
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22R M Sharkey, T M Behr, M J Mattes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical studyT M Behr, A L Salib, T Liersch, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Cancer Research|December 11, 1997
Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor typeT M Behr, E Wulst, S Radetzky, et al.
Radiation Research|February 22, 2001
Response to radioimmunotherapy correlates with tumor pO2 measured by EPR oximetry in human tumor xenograftsJ A O'Hara, R D Blumenthal, O Y Grinberg, et al.
Cancer Research|December 1, 1995
Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studiesR M Sharkey, M Juweid, J Shevitz, et al.
International Journal of Cancer|August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacyT M Behr, S Memtsoudis, R M Sharkey, et al.
Cancer|December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetryT M Behr, R M Sharkey, G Sgouros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emittersT M Behr, G Sgouros, M G Stabin, et al.
Cancer Research|September 1, 1995
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivativesT M Behr, R M Sharkey, M E Juweid, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1997
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22R M Sharkey, T M Behr, M J Mattes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical studyT M Behr, A L Salib, T Liersch, et al.
Pageof 6